One-Stop Allogeneic Cell Therapy Development Solutions
End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.
One-Stop Allogeneic Cell Therapy Development Solutions
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Creative Biolabs supports one‑stop development of allogeneic, off‑the‑shelf cell therapies, enabling donor sourcing/qualification, genome editing for GVHD/immune evasion, and modular manufacturing designed for consistency, cost, and access.
The platform accommodates CAR‑T/CAR‑NK and other donor‑derived cell products, providing editing strategies (e.g., TCR/β2M/CIITA knock‑out, HLA engineering), scalability studies, and IND‑enabling documentation.
Key Features / Benefits
- Donor material strategy and qualification; iPSC or peripheral blood starting materials
- Multiplex genome editing for safety and immune evasion (TCR, B2M, CIITA, HLA)
- Process scale‑up and comparability for off‑the‑shelf manufacturing
- Regulatory/IND support and CMC documentation alignment
Relevant Applications
- Allogeneic CAR‑T/CAR‑NK programs targeting scalable, consistent supply
- Editing‑enabled safety/engraftment strategies for off‑the‑shelf products
- CMC and IND‑enabling packages for first‑in‑human
